Use of botulinum neurotoxin in the treatment of sialorrhea

A method for treating a disease or condition associated with sialorrhea or increased saliva production in a patient, the method comprising administering a therapeutically effective amount of a botulinum neurotoxin by injection into the parotid glands and submandibular glands of the patient in at least four consecutive treatment cycles,

• wherein the disease or condition is further associated with stroke, traumatic brain injury (TBI), clozapine induced hypersalivation, Rett syndrome, Angelman syndrome, epileptic encephalopathy, brain tumours, or intellectual disability,
• wherein there is a time interval between the consecutive treatment cycles of between 14 and 18 weeks,
• wherein each treatment cycle comprises administering the botulinum neurotoxin in a total dose between 1 and 2.5 U/Kg body weight, and the total dose of the botulinum neurotoxin administered into the parotid glands and submandibular glands is between 20 U and 75 U,
• and wherein the ratio between the amount of the botulinum neurotoxin administered into each of the parotid glands and each of the submandibular glands is between 1.45 to 1 and 1.7 to 1.